Select Publications
2024
Sarmiento Bustamante, M., Pierson, S.K., Ren, Y., Bagg, A., Brandstadter, J.D., Srkalovic, G., Mango, N., Alapat, D., Lechowicz, MJ., Li, H., van Rhee, F., Lim, M.S., & Fajgenbaum, D.C. (2024). Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Haematologica, online ahead of print. https://doi.org/10.3324/haematol.2023.283603
Rubenstein, A.I., Pierson, S.K., Shyamsundar, S., Sarmiento Bustamante, M., Gonzalez, M.V., Milller, I.D., Brandstadter, J.D., Mumau, M.D., & Fajgenbaum, D.C. (2024). Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British Journal of Haematology, online ahead of print. https://doi.org/10.1111/bjh.19279
2023
Sarmiento Bustamante, M., Shyamsundar, S., Coren, F.R., Adam Bagg, A., Srkalovic, G., Alapat, D., van Rhee, F., Lim, M.S., Lechowicz, MJ., Brandstadter, J.D., Pierson, S.K., & Fajgenbaum, D.C. (2023). Ongoing symptoms following complete surgical excision in unicentric Castleman disease." American Journal of Hematology, 98(11), E334-E337. https://doi.org/10.1002/ajh.27065
Korsunska, A., Repasky, M., Zuccato, M., & Fajgenbaum, D.C. (2023). A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases. Orphanet Journal of Rare Disease, 18(1), 75. https://doi.org/10.1186/s13023-023-02678-6
Pierson, S.K., Lim, M.S., Srkalovic, G., Brandstadter, J.D., Sarmiento Bustamante, M., Shyamsundar, S., Mango, N., Lavery, C., Austin, B., Alapat, D., Lechowicz, MJ., Bagg, A., Li, H., 8, Casper, C., van Rhee, F., & Fajgenbaum, D.C. (2023). Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Advances, 7(21): 6652-6664. https://doi.org/10.1182/bloodadvances.2023010745
Mango, N.A., Pierson, S.K., Sarmiento Bustamante, M., Brandstadter, J.D., van Rhee, F., & Fajgenbaum, D.C. (2023) Siltuximab administration results in spurious IL-6 elevation in peripheral blood. American Journal of Hematology. 99(1); E15-E18. https://doi.org/10.1002/ajh.27132
Horna, P., King. R.L., Jevremovic, D., Fajgenbaum, D.C., & Dispenzieri, A. (2023). The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease. Haematologica, 108(1), 207-218. https://doi.org/10.3324/haematol.2021.280370
Rodolfi, S., Della-Torre, E., Bongiovanni, L., Mehta, P., Fajgenbaum, D.C., & Carlo Selmi, C. (2023) Lymphadenopathy in the rheumatology practice: a pragmatic approach. Rheumatology (Oxford). kead644. https://doi.org/10.1093/rheumatology/kead644
Brandstadter, J. D., De Martin, A., Lütge, M., Ferreira, A., Gaudette, B. T., Stanossek, Y., Wang, S., Gonzalez, M. V., Camiolo, E., Wertheim, G., Austin, B., Allman, D., Lim, M. S., Fajgenbaum, D. C., Aster, J. C., Ludewig, B., & Maillard, I. (2023). A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease. bioRxiv : the preprint server for biology, 2023.02.06.525604. https://doi.org/10.1101/2023.02.06.525604
2022
Hoffmann, C., Wechselberger, T., Drexel, H., Dertinger, S., Dirnhofer, S., Pierson, S.K., Fajgenbaum, D.C., & Kessler A. (2022). Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine. Vaccines (Basel), 10(10), 1725. https://doi.org/10.3390/vaccines10101725
Brandstadter, J.D., & David, C. Fajgenbaum D.C. (2022). How We Manage Idiopathic Multicentric Castleman Disease. Clinical Advances in Hematology Oncology, 20(1), 564-571. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9584165/
Pierson, S. K., Katz, L., Williams, R., Mumau, M., Gonzalez, M., Guzman, S., Rubenstein, A., Oromendia, A. B., Beineke, P., Fosså, A., van Rhee, F., & Fajgenbaum, D. C. (2022). CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. Nature Communications, 13(1), 7236. https://doi.org/10.1038/s41467-022-34873-7
Fajgenbaum, D. C., Pierson, S. K., Kanhai, K., Bagg, A., Alapat, D., Lim, M. S., Lechowicz, M. J., Srkalovic, G., Uldrick, T. S., van Rhee, F., & ACCELERATE Registry Team. (2022). The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry. British Journal of Haematology, 198(2), 307–316. https://doi.org/10.1111/bjh.18214
Horna, P., King, R. L., Jevremovic, D., Fajgenbaum, D. C., & Dispenzieri, A. (2022). The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease. Haematologica. https://doi.org/10.3324/haematol.2021.280370
Wing, A., Xu, J., Meng, W., Rosenfeld, A. M., Li, E. Y., Wertheim, G., Paessler, M., Bagg, A., Frank, D., Tan, K., Teachey, D. T., Lim, M. S., Prak, E. L., Fajgenbaum, D. C., & Pillai, V. (2022). Transcriptome and unique cytokine microenvironment of Castleman disease. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, 35(4), 451–461. https://doi.org/10.1038/s41379-021-00950-3
Belyaeva, E., Rubenstein, A., Pierson, S. K., Dalldorf, D., Frank, D., Lim, M. S., & Fajgenbaum, D. C. (2022). Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. Hematological oncology, 40(2), 191–201. https://doi.org/10.1002/hon.2969
Phillips, A. D., Kakkis, J. J., Tsao, P. Y., Pierson, S. K., & Fajgenbaum, D. C. (2022). Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. Journal of cellular and molecular medicine, 26(11), 3147–3152. https://doi.org/10.1111/jcmm.17251
Mukherjee, S., Martin, R., Sande, B., Paige, J. S., & Fajgenbaum, D. C. (2022). Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood advances, 6(2), 359–367. https://doi.org/10.1182/bloodadvances.2021004441
Zhang, L., Zhang, M. Y., Cao, X. X., Zhou, D. B., Fajgenbaum, D. C., Dong, Y. J., & Li, J. (2022). A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leukemia & lymphoma, 63(3), 618–626. https://doi.org/10.1080/10428194.2021.1999437
2021
Goodman, A. M., Jeong, A. R., Phillips, A., Wang, H. Y., Sokol, E. S., Cohen, P. R., Sicklick, J., Fajgenbaum, D. C., & Kurzrock, R. (2021). Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. European journal of haematology, 107(6), 642–649. https://doi.org/10.1111/ejh.13702
Nishimura, Y., Fajgenbaum, D. C., Pierson, S. K., Iwaki, N., Nishikori, A., Kawano, M., Nakamura, N., Izutsu, K., Takeuchi, K., Nishimura, M. F., Maeda, Y., Otsuka, F., Yoshizaki, K., Oksenhendler, E., van Rhee, F., & Sato, Y. (2021). Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. American journal of hematology, 96(10), 1241–1252. https://doi.org/10.1002/ajh.26292
Pierson, S. K., Shenoy, S., Oromendia, A. B., Gorzewski, A. M., Langan Pai, R. A., Nabel, C. S., Ruth, J. R., Parente, S. A. T., Arenas, D. J., Guilfoyle, M., Reddy, M., Weinblatt, M., Shadick, N., Bower, M., Pria, A. D., Masaki, Y., Katz, L., Mezey, J., Beineke, P., Lee, D., … Fajgenbaum, D. C. (2021). Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood advances, 5(17), 3445–3456. https://doi.org/10.1182/bloodadvances.2020004016
Lim, J. Y., Duttke, S. H., Baker, T. S., Lee, J., Gambino, K. J., Venturini, N. J., Ho, J. S. Y., Zheng, S., Fstkchyan, Y. S., Pillai, V., Fajgenbaum, D. C., Marazzi, I., Benner, C., & Byun, M. (2021). DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. The Journal of experimental medicine, 218(7), e20202733. https://doi.org/10.1084/jem.20202733
Koa, B., Borja, A. J., Aly, M., Padmanabhan, S., Tran, J., Zhang, V., Rojulpote, C., Pierson, S. K., Tamakloe, M. A., Khor, J. S., Werner, T. J., Fajgenbaum, D. C., Alavi, A., & Revheim, M. E. (2021). Emerging role of 18F-FDG PET/CT in Castleman disease: a review. Insights into imaging, 12(1), 35. https://doi.org/10.1186/s13244-021-00963-1
Zhang, M. Y., Jia, M. N., Chen, J., Feng, J., Cao, X. X., Zhou, D. B., Fajgenbaum, D. C., Zhang, L., & Li, J. (2021). UCD with MCD-like inflammatory state: surgical excision is highly effective. Blood advances, 5(1), 122–128. https://doi.org/10.1182/bloodadvances.2020003607
Kawano, M., Hara, S., Yachie, A., Inoue, D., Sato, Y., & Fajgenbaum, D. C. (2021). HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease. Rheumatology (Oxford, England), 60(1), e3–e4. https://doi.org/10.1093/rheumatology/keaa362
2020
Abdallah, H., Porterfield, F., & Fajgenbaum, D.C. (2020). Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man. BMJ case reports, 13(12), e239825. https://doi.org/10.1136/bcr-2020-239825
Fajgenbaum, D. C., Wu, D., Goodman, A., Wong, R., Chadburn, A., Nasta, S., Srkalovic, G., Mukherjee, S., Leitch, H., Jayanthan, R., Ferrero, S., Sato, Y., Schey, S., Dispenzieri, A., Oksenhendler, E., Zinzani, P. L., Lechowicz, M. J., Hoffmann, C., Pemmaraju, N., Bagg, A., … Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group (2020). Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. American journal of hematology, 95(12), 1553–1561. https://doi.org/10.1002/ajh.25992
Fajgenbaum, D. C., & Phillips, A. D. (2020). Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. Clinical chemistry, 66(11), 1378–1379. https://doi.org/10.1093/clinchem/hvaa156
Fajgenbaum, D. C., & Rader, D. J. (2020). Teaching Old Drugs New Tricks: Statins for COVID-19?. Cell metabolism, 32(2), 145–147. https://doi.org/10.1016/j.cmet.2020.07.006
Fajgenbaum, D. C., Khor, J. S., Gorzewski, A., Tamakloe, M. A., Powers, V., Kakkis, J. J., Repasky, M., Taylor, A., Beschloss, A., Hernandez-Miyares, L., Go, B., Nimgaonkar, V., McCarthy, M. S., Kim, C. J., Pai, R. L., Frankl, S., Angelides, P., Jiang, J., Rasheed, R., Napier, E., … Pierson, S. K. (2020). Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. Infectious diseases and therapy, 9(3), 435–449. https://doi.org/10.1007/s40121-020-00303-8
Pai, R. L., Japp, A. S., Gonzalez, M., Rasheed, R. F., Okumura, M., Arenas, D., Pierson, S. K., Powers, V., Layman, A. A. K., Kao, C., Hakonarson, H., van Rhee, F., Betts, M. R., Kambayashi, T., & Fajgenbaum, D. C. (2020). Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI insight, 5(9), e135031.
Arenas, D. J., Floess, K., Kobrin, D., Pai, R. L., Srkalovic, M. B., Tamakloe, M. A., Rasheed, R., Ziglar, J., Khor, J., Parente, S. A. T., Pierson, S. K., Martinez, D., Wertheim, G. B., Kambayashi, T., Baur, J., Teachey, D. T., & Fajgenbaum, D. C. (2020). Increased mTOR activation in idiopathic multicentric Castleman disease. Blood, 135(19), 1673–1684. https://doi.org/10.1182/blood.2019002792
Dispenzieri, A., & Fajgenbaum, D. C. (2020). Overview of Castleman disease. Blood, 135(16), 1353–1364. https://doi.org/10.1182/blood.2019000931
Yoshimi, A., Trippett, T. M., Zhang, N., Chen, X., Penson, A. V., Arcila, M. E., Pichardo, J., Baik, J., Sigler, A., Harada, H., Fajgenbaum, D. C., Dogan, A., Abdel-Wahab, O., & Xiao, W. (2020). Genetic basis for iMCD-TAFRO. Oncogene, 39(15), 3218–3225. https://doi.org/10.1038/s41388-020-1204-9
Bernabei, L., Waxman, A., Caponetti, G., Fajgenbaum, D. C., & Weiss, B. M. (2020). AA amyloidosis associated with Castleman disease: A case report and review of the literature. Medicine, 99(6), e18978. https://doi.org/10.1097/MD.0000000000018978
2019
Suarez, A., Reilly, C., & Fajgenbaum, D. C. (2019). Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era. Orphanet journal of rare diseases, 14(1), 173. https://doi.org/10.1186/s13023-019-1145-y
Fajgenbaum, D. C., Langan, R. A., Japp, A. S., Partridge, H. L., Pierson, S. K., Singh, A., Arenas, D. J., Ruth, J. R., Nabel, C. S., Stone, K., Okumura, M., Schwarer, A., Jose, F. F., Hamerschlak, N., Wertheim, G. B., Jordan, M. B., Cohen, A. D., Krymskaya, V., Rubenstein, A., Betts, M. R., … Uldrick, T. S. (2019). Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. The Journal of clinical investigation, 129(10), 4451–4463. https://doi.org/10.1172/JCI126091
Nabel, C. S., Sameroff, S., Shilling, D., Alapat, D., Ruth, J. R., Kawano, M., Sato, Y., Stone, K., Spetalen, S., Valdivieso, F., Feldman, M. D., Chadburn, A., Fosså, A., van Rhee, F., Lipkin, W. I., & Fajgenbaum, D. C. (2019). Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease. PloS one, 14(6), e0218660. https://doi.org/10.1371/journal.pone.0218660
Kobrin, D. M., Pinto, A. L., Parente, S. T., Gomes, M., Cipriano, M. A., Ribeiro, M. L., & Fajgenbaum, D. C. (2019). Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'. Acta oncologica (Stockholm, Sweden), 58(4), 515–517. https://doi.org/10.1080/0284186X.2019.1574980
Zhang, L., Zhao, A. L., Duan, M. H., Li, Z. Y., Cao, X. X., Feng, J., Zhou, D. B., Zhong, D. R., Fajgenbaum, D. C., & Li, J. (2019). Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood, 133(16), 1720–1728. https://doi.org/10.1182/blood-2018-11-884577
Zuccato, M., Shilling, D., & Fajgenbaum, D. C. (2019). The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. Emerging topics in life sciences, 3(1), 97–105. https://doi.org/10.1042/ETLS20180178
Leurs, A., Gnemmi, V., Lionet, A., Renaud, L., Gibier, J. B., Copin, M. C., Hachulla, E., Hatron, P. Y., Launay, D., Fajgenbaum, D.C., & Terriou, L. (2019). Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Frontiers in immunology, 10, 1489. https://doi.org/10.3389/fimmu.2019.01489
Morra, D. E., Pierson, S. K., Shilling, D., Nemat, S., Appiani, C., Guilfoyle, M., Tendler, C., van Rhee, F., & Fajgenbaum, D. C. (2019). Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. British journal of haematology, 184(2), 232–241. https://doi.org/10.1111/bjh.15588
2018
Fajgenbaum D. C. (2018). Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood, 132(22), 2323–2330. https://doi.org/10.1182/blood-2018-05-848671
van Rhee, F., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalovic, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S. K., Partridge, H. L., Mukherjee, S., Shilling, D., Stone, K., Greenway, A., Ruth, J., Lechowicz, M. J., Chandrakasan, S., Jayanthan, R., Jaffe, E. S., … Fajgenbaum, D. C. (2018). International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 132(20), 2115–2124. https://doi.org/10.1182/blood-2018-07-862334
Dong, Y., Zhang, L., Nong, L., Wang, L., Liang, Z., Zhou, D., Fajgenbaum, D. C., Ren, H., & Li, J. (2018). Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Annals of hematology, 97(9), 1641–1647. https://doi.org/10.1007/s00277-018-3347-0
Baker, T. S., Gambino, K. J., Schriefer, L., Lim, J. Y., Steinberg, K. M., Fajgenbaum, D. C., Martín García-Sancho, A., & Byun, M. (2018). A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. Blood advances, 2(21), 2959–2963. https://doi.org/10.1182/bloodadvances.2018023911
Pierson, S. K., Stonestrom, A. J., Shilling, D., Ruth, J., Nabel, C. S., Singh, A., Ren, Y., Stone, K., Li, H., van Rhee, F., & Fajgenbaum, D. C. (2018). Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. American journal of hematology, 93(7), 902–912. https://doi.org/10.1002/ajh.25123
Lee, J., Werth, V. P., Hall, R. P., 3rd, Eming, R., Fairley, J. A., Fajgenbaum, D. C., Harman, K. E., Jonkman, M. F., Korman, N. J., Ludwig, R. J., Murrell, D. F., Musette, P., Naik, H. B., Sadik, C. D., Yamagami, J., Yale, M. L., & Payne, A. S. (2018). Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. Frontiers in medicine, 5, 306. https://doi.org/10.3389/fmed.2018.00306
Fajgenbaum, D. C., & Shilling, D. (2018). Castleman Disease Pathogenesis. Hematology/oncology clinics of North America, 32(1), 11–21. https://doi.org/10.1016/j.hoc.2017.09.002
Soudet, S., Fajgenbaum, D.C., Delattre, C., Forestier, A., Hachulla, E., Hatron, P. Y., Launay, D., & Terriou, L. (2018). Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. Current research in translational medicine, 66(3), 83–86. https://doi.org/10.1016/j.retram.2018.06.001
2017
Louis, C., Vijgen, S., Samii, K., Chalandon, Y., Terriou, L., Launay, D., Fajgenbaum, D. C., Seebach, J. D., & Muller, Y. D. (2017). TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. Frontiers in medicine, 4, 149. https://doi.org/10.3389/fmed.2017.00149
Srkalovic, G., Marijanovic, I., Srkalovic, M. B., & Fajgenbaum, D. C. (2017). TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. Bosnian journal of basic medical sciences, 17(2), 81–84. https://doi.org/10.17305/bjbms.2017.1930
Yu, L., Tu, M., Cortes, J., Xu-Monette, Z. Y., Miranda, R. N., Zhang, J., Orlowski, R. Z., Neelapu, S., Boddu, P. C., Akosile, M. A., Uldrick, T. S., Yarchoan, R., Medeiros, L. J., Li, Y., Fajgenbaum, D. C., & Young, K. H. (2017). Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood, 129(12), 1658–1668.
Fajgenbaum, D. C., Uldrick, T. S., Bagg, A., Frank, D., Wu, D., Srkalovic, G., Simpson, D., Liu, A. Y., Menke, D., Chandrakasan, S., Lechowicz, M. J., Wong, R. S., Pierson, S., Paessler, M., Rossi, J. F., Ide, M., Ruth, J., Croglio, M., Suarez, A., Krymskaya, V., … Lim, M. S. (2017). International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood, 129(12), 1646–1657. https://doi.org/10.1182/blood-2016-10-746933
Behnia, F., Elojeimy, S., Matesan, M., & Fajgenbaum, D. C. (2017). Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome. Annals of hematology, 96(3), 497–500. https://doi.org/10.1007/s00277-016-2875-8
2016
Liu, A. Y., Nabel, C. S., Finkelman, B. S., Ruth, J. R., Kurzrock, R., van Rhee, F., Krymskaya, V. P., Kelleher, D., Rubenstein, A. H., & Fajgenbaum, D. C. (2016). Idiopathic multicentric Castleman's disease: a systematic literature review. The Lancet. Haematology, 3(4), e163–e175. https://doi.org/10.1016/S2352-3026(16)00006-5
Fajgenbaum, D. C., Ruth, J. R., Kelleher, D., & Rubenstein, A. H. (2016). The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. The Lancet. Haematology, 3(4), e150–e152. https://doi.org/10.1016/S2352-3026(16)00007-7
Iwaki, N., Fajgenbaum, D. C., Nabel, C. S., Gion, Y., Kondo, E., Kawano, M., Masunari, T., Yoshida, I., Moro, H., Nikkuni, K., Takai, K., Matsue, K., Kurosawa, M., Hagihara, M., Saito, A., Okamoto, M., Yokota, K., Hiraiwa, S., Nakamura, N., Nakao, S., … Sato, Y. (2016). Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. American journal of hematology, 91(2), 220–226. https://doi.org/10.1002/ajh.24242
Fajgenbaum, D. C., & Kurzrock, R. (2016). Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy, 8(1), 17–26. https://doi.org/10.2217/imt.15.95
2015
Newman, S. K., Jayanthan, R. K., Mitchell, G. W., Carreras Tartak, J. A., Croglio, M. P., Suarez, A., Liu, A. Y., Razzo, B. M., Oyeniran, E., Ruth, J. R., & Fajgenbaum, D. C. (2015). Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. The Yale journal of biology and medicine, 88(4), 383–388.
2014
Fajgenbaum, D. C., van Rhee, F., & Nabel, C. S. (2014). HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood, 123(19), 2924–2933. https://doi.org/10.1182/blood-2013-12-545087
Fajgenbaum, D. C., Rosenbach, M., van Rhee, F., Nasir, A., & Reutter, J. (2013). Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA dermatology, 149(2), 204–208. https://doi.org/10.1001/jamadermatol.2013.1552